Japan has become one of the most strategically important markets for oncology development, offering a unique combination of regulatory support, globally accepted data, and operational consistency. Across operational benchmarks spanning 15 developed clinical trial countries, Japan consistently demonstrates top-performing efficiency. Navigating this landscape successfully requires both local oncology insight and global coordination to help sponsors manage complexity from study start-up through database lock.  

In the Topic Guide, you will learn how Japan delivers:

• Fastest Data Entry: Across 15 developed trial markets.  
• Faster Queries: Strong site and data performance.  
• Fewer Data Corrections: Cleaner oncology data.  
• Lower Screening Failures: More efficient patient matching.  
• A Partnership Built for Oncology: How A2 Healthcare and Medidata combine local oncology expertise with connected clinical technology across 100+ joint studies.